Rachna Rastogi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rachna Rastogi has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Patrick Franklin Kiser
Department of Biomedical Engineering, Northwestern University, Evanston, Illinois, USA
7 shared publications Veena Koul
7 shared publicationsRyan S. Teller
Department of Bioengineering, University of Utah, 20 S 2030 E, Salt Lake City, UT 84112, United States; Department of Biomedical Engineering, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, United States
5 shared publicationsSneh Anand
5 shared publications- Pedro M. M. Mesquita
Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, USA
4 shared publications - Mohammed Aqil
Department of Pharmaceutics, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi 110062, India
3 shared publications
Latest Publications
- 1 June 2025
- Published by Bentham Science Publishers Ltd. in Applied Drug Research, Clinical Trials and Regulatory Affairs
- Vol. 11, 1-7
A Multicomponent Eye Cream Helps Alleviate Signs of Aging in Indian Women: A Single Center, Non-Randomized Clinical Study
Introduction: The area around the eye shows the first signs of fatigue and aging. The use of suitable topical treatments can help manage the periorbital area. In this study, the efficacy of a multicomponent cream in improving the aesthetics around the eye area was examined in 8 weeks. Methods: The study was a non-comparative, single-blind trial conducted on 50 Indian volunteers with skin types III and IV for 56 days. The safety and cosmetic acceptability of the eye cream were determined by self-evaluation. The ability of the product to improve skin hydration and elasticity was determined by instrumental analysis and aesthetic features by dermatologist evaluation. Results: Results: In an 8-week assessment, the use of the eye cream twice daily resulted in improved skin hydration by 55.82% compared to baseline. A significant reduction in the appearance of dark circles under the eye, puffiness, wrinkles, and fine lines was reported. Conclusion: While the skin around the eyes shows early signs of aging, regular use of cosmetic creams with active components, such as peptides and niacinamide, can lead to significant improvement in overall aesthetic appearance.
- 1 June 2025
- Published by Bentham Science Publishers Ltd. in Applied Drug Research, Clinical Trials and Regulatory Affairs
- Vol. 11, 1-7
A Multicomponent Eye Cream Helps Alleviate Signs of Aging in Indian Women: A Single Center, Non-Randomized Clinical Study
Introduction: The area around the eye shows the first signs of fatigue and aging. The use of suitable topical treatments can help manage the periorbital area. In this study, the efficacy of a multicomponent cream in improving the aesthetics around the eye area was examined in 8 weeks. Methods: The study was a non-comparative, single-blind trial conducted on 50 Indian volunteers with skin types III and IV for 56 days. The safety and cosmetic acceptability of the eye cream were determined by self-evaluation. The ability of the product to improve skin hydration and elasticity was determined by instrumental analysis and aesthetic features by dermatologist evaluation. Results: Results: In an 8-week assessment, the use of the eye cream twice daily resulted in improved skin hydration by 55.82% compared to baseline. A significant reduction in the appearance of dark circles under the eye, puffiness, wrinkles, and fine lines was reported. Conclusion: While the skin around the eyes shows early signs of aging, regular use of cosmetic creams with active components, such as peptides and niacinamide, can lead to significant improvement in overall aesthetic appearance.
- 26 October 2023
- Published by Bentham Science Publishers Ltd. in Current Cosmetic Science
- Vol. 02, 1
Combination of Sodium Hyaluronate, Withania Somnifera Extract and Niacinamide Improves Hydration and Skin Tone – A Clinical Study
Background: Multiple moisturizing solutions with sodium hyaluronate, Withania sominifera, and niacinamide are commercially popular. Detailed clinical studies portraying their activity are not available. Objective: This study aims to study the clinical efficacy of a phyto-bioactive cream in improving skin hydration and tone with 4 weeks of continuous usage. Methodology: We conducted a non-comparative, single-blind study on 50 Asian female volunteers with Fitzpatrick skin types III and IV for 28 days. Cosmetic acceptability and safety of the product were established via self-evaluation questionnaires. The ability of the topical formulation in maintaining skin tone, hydration, and firmness was determined by instrumental analysis and smoothness by dermatologist evaluation. Results: A total of 46 subjects completed the study. High levels of skin hydration were noted instantaneously (+61.11%) and post continuous use of the product. Significant reduction in the appearance of age/dark spots (ITA°), Δ ITA°= 37.49% and increase in skin lightness (L) by 2.66% compared to baseline was observed in 4 weeks. More than 80% of the subjects reported an increase in skin firmness and smoothness in 4 weeks of twice-a-day product usage. Conclusion: Our study establishes the safety and acceptability of the phyto-bioactive cream. The efficiency of the combination of Withania somnifera extract, sodium hyaluronate, and niacinamide in improving skin hydration and tone has been proven.
- 26 October 2023
- Published by Bentham Science Publishers Ltd. in Current Cosmetic Science
- Vol. 02, 1
Combination of Sodium Hyaluronate, Withania Somnifera Extract and Niacinamide Improves Hydration and Skin Tone – A Clinical Study
Background: Multiple moisturizing solutions with sodium hyaluronate, Withania sominifera, and niacinamide are commercially popular. Detailed clinical studies portraying their activity are not available. Objective: This study aims to study the clinical efficacy of a phyto-bioactive cream in improving skin hydration and tone with 4 weeks of continuous usage. Methodology: We conducted a non-comparative, single-blind study on 50 Asian female volunteers with Fitzpatrick skin types III and IV for 28 days. Cosmetic acceptability and safety of the product were established via self-evaluation questionnaires. The ability of the topical formulation in maintaining skin tone, hydration, and firmness was determined by instrumental analysis and smoothness by dermatologist evaluation. Results: A total of 46 subjects completed the study. High levels of skin hydration were noted instantaneously (+61.11%) and post continuous use of the product. Significant reduction in the appearance of age/dark spots (ITA°), Δ ITA°= 37.49% and increase in skin lightness (L) by 2.66% compared to baseline was observed in 4 weeks. More than 80% of the subjects reported an increase in skin firmness and smoothness in 4 weeks of twice-a-day product usage. Conclusion: Our study establishes the safety and acceptability of the phyto-bioactive cream. The efficiency of the combination of Withania somnifera extract, sodium hyaluronate, and niacinamide in improving skin hydration and tone has been proven.
- 1 February 2016
- Published by Elsevier in Journal of Controlled Release
- Vol. 224, 176-183
Controlling the hydration rate of a hydrophilic matrix in the core of an intravaginal ring determines antiretroviral release
- 1 February 2016
- Published by Elsevier in Journal of Controlled Release
- Vol. 224, 176-183
Controlling the hydration rate of a hydrophilic matrix in the core of an intravaginal ring determines antiretroviral release
- 13 November 2015
- Published by Elsevier in Contraception
- Vol. 93 (4) , 337-346
Engineering and characterization of simplified vaginal and seminal fluid simulants
- 13 November 2015
- Published by Elsevier in Contraception
- Vol. 93 (4) , 337-346
Engineering and characterization of simplified vaginal and seminal fluid simulants
- 1 October 2014
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 30 (S1) , A67-A68
A Simple Intravaginal Ring Pump for Sustained Vaginal Release of ARV Microparticles and Macromolecular Agents
- 1 October 2014
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 30 (S1) , A67-A68
A Simple Intravaginal Ring Pump for Sustained Vaginal Release of ARV Microparticles and Macromolecular Agents
- 2 May 2014
- Published by Springer Nature in Pharmaceutical Research
- Vol. 31 (9) , 2344-2353
Intravaginal Flux Controlled Pump for Sustained Release of Macromolecules
To design a flux controlled pump (FCP) capable of 30-day, controlled release of macromolecules to the vaginal mucosa. The FCP is composed of a single chamber fabricated from a rigid thermoplastic with orifices and encloses a pellet of water-swellable polymer containing the drug substance. We performed testing both in vitro and in rabbits. To ensure vaginal retention in the rabbit, we designed and attached an oval shape-memory polyether urethane retainer to the FCP allowing for long-term intravaginal evaluation of a solid dosage form without invasive surgical implantation. The orifices and swelling properties of the polymer pellet control water entry for polymer hydration and expansion, and subsequent extrusion of the drug-containing gel from the orifice. A FCP device containing a pellet composed of hydroxypropyl cellulose compounded with a model macromolecule, achieved controlled in vitro release for 30 days with an average release rate of 24 ± 2 μg/day (mean ± SD) and range of 16 to 42 μg/day. We observed a slightly lower average release rate in vivo of 20 ± 0.6 μg/day (mean ± SD). The size of the orifice and nature of the swelling polymer controls the hydration rate and thereby macromolecule release rate and duration from this FCP.
- 2 May 2014
- Published by Springer Nature in Pharmaceutical Research
- Vol. 31 (9) , 2344-2353
Intravaginal Flux Controlled Pump for Sustained Release of Macromolecules
To design a flux controlled pump (FCP) capable of 30-day, controlled release of macromolecules to the vaginal mucosa. The FCP is composed of a single chamber fabricated from a rigid thermoplastic with orifices and encloses a pellet of water-swellable polymer containing the drug substance. We performed testing both in vitro and in rabbits. To ensure vaginal retention in the rabbit, we designed and attached an oval shape-memory polyether urethane retainer to the FCP allowing for long-term intravaginal evaluation of a solid dosage form without invasive surgical implantation. The orifices and swelling properties of the polymer pellet control water entry for polymer hydration and expansion, and subsequent extrusion of the drug-containing gel from the orifice. A FCP device containing a pellet composed of hydroxypropyl cellulose compounded with a model macromolecule, achieved controlled in vitro release for 30 days with an average release rate of 24 ± 2 μg/day (mean ± SD) and range of 16 to 42 μg/day. We observed a slightly lower average release rate in vivo of 20 ± 0.6 μg/day (mean ± SD). The size of the orifice and nature of the swelling polymer controls the hydration rate and thereby macromolecule release rate and duration from this FCP.
- Open Access
- 24 October 2013
- Published by Springer Nature in Retrovirology
- Vol. 10 (1) , 113
Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties
The limited success of recent HIV topical pre-exposure prophylaxis clinical trials highlights the need for more predictive models of drug efficacy that better simulate what may happen during sexual exposure. To address this gap, we developed complementary in vitro models to evaluate the ability of drugs to retain anti-HIV activity if cells were washed with seminal plasma (simulating what may happen following exposure to ejaculate), and to protect drug-naive T cells (representing newly recruited immune cells) co-cultured with explants that had been pretreated with drug. We focused on tenofovir disoproxil fumarate (TDF), the non-nucleoside reverse transcriptase inhibitors dapivirine (DPV) and IQP-0528, and the entry inhibitors maraviroc (MVC) and the D-peptide chol-PIE-12 trimer (PIE12). Studies were extended to macaques and the ability of cervical biopsies obtained from animals treated with an intravaginal ring formulation of IQP-0528 to protect ex vivo co-cultured T cells was determined. The antiviral activity of cervicovaginal lavage samples against a primary Clade C isolate was also measured and correlated with drug levels.
- 24 October 2013
- Published by Springer Nature in Retrovirology
- Vol. 10 (1) , 113
Open AccessNovel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties
The limited success of recent HIV topical pre-exposure prophylaxis clinical trials highlights the need for more predictive models of drug efficacy that better simulate what may happen during sexual exposure. To address this gap, we developed complementary in vitro models to evaluate the ability of drugs to retain anti-HIV activity if cells were washed with seminal plasma (simulating what may happen following exposure to ejaculate), and to protect drug-naive T cells (representing newly recruited immune cells) co-cultured with explants that had been pretreated with drug. We focused on tenofovir disoproxil fumarate (TDF), the non-nucleoside reverse transcriptase inhibitors dapivirine (DPV) and IQP-0528, and the entry inhibitors maraviroc (MVC) and the D-peptide chol-PIE-12 trimer (PIE12). Studies were extended to macaques and the ability of cervical biopsies obtained from animals treated with an intravaginal ring formulation of IQP-0528 to protect ex vivo co-cultured T cells was determined. The antiviral activity of cervicovaginal lavage samples against a primary Clade C isolate was also measured and correlated with drug levels.
- 1 October 2013
- Published by Elsevier in Antiviral Research
- Vol. 100 (1) , 255-258
Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa
- 1 October 2013
- Published by Elsevier in Antiviral Research
- Vol. 100 (1) , 255-258
Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa
- 16 September 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (40) , 16145-16150
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges
Topical preexposure prophylaxis interrupts HIV transmission at the site of mucosal exposure. Intermittently dosed vaginal gels containing the HIV-1 reverse transcriptase inhibitor tenofovir protected pigtailed macaques depending on the timing of viral challenge relative to gel application. However, modest or no protection was observed in clinical trials. Intravaginal rings (IVRs) may improve efficacy by providing long-term sustained drug delivery leading to constant mucosal antiretroviral concentrations and enhancing adherence. Although a few IVRs have entered the clinical pipeline, 100% efficacy in a repeated macaque vaginal challenge model has not been achieved. Here we describe a reservoir IVR technology that delivers the tenofovir prodrug tenofovir disoproxil fumarate (TDF) continuously over 28 d. With four monthly ring changes in this repeated challenge model, TDF IVRs generated reproducible and protective drug levels. All TDF IVR-treated macaques (n = 6) remained seronegative and simian-HIV RNA negative after 16 weekly vaginal exposures to 50 tissue culture infectious dose SHIV162p3. In contrast, 11/12 control macaques became infected, with a median of four exposures assuming an eclipse of 7 d from infection to virus RNA detection. Protection was associated with tenofovir levels in vaginal fluid [mean 1.8 × 105 ng/mL (range 1.1 × 104 to 6.6 × 105 ng/mL)] and ex vivo antiviral activity of cervicovaginal lavage samples. These observations support further advancement of TDF IVRs as well as the concept that extended duration drug delivery devices delivering topical antiretrovirals could be effective tools in preventing the sexual transmission of HIV in humans.
- 16 September 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (40) , 16145-16150
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges
Topical preexposure prophylaxis interrupts HIV transmission at the site of mucosal exposure. Intermittently dosed vaginal gels containing the HIV-1 reverse transcriptase inhibitor tenofovir protected pigtailed macaques depending on the timing of viral challenge relative to gel application. However, modest or no protection was observed in clinical trials. Intravaginal rings (IVRs) may improve efficacy by providing long-term sustained drug delivery leading to constant mucosal antiretroviral concentrations and enhancing adherence. Although a few IVRs have entered the clinical pipeline, 100% efficacy in a repeated macaque vaginal challenge model has not been achieved. Here we describe a reservoir IVR technology that delivers the tenofovir prodrug tenofovir disoproxil fumarate (TDF) continuously over 28 d. With four monthly ring changes in this repeated challenge model, TDF IVRs generated reproducible and protective drug levels. All TDF IVR-treated macaques (n = 6) remained seronegative and simian-HIV RNA negative after 16 weekly vaginal exposures to 50 tissue culture infectious dose SHIV162p3. In contrast, 11/12 control macaques became infected, with a median of four exposures assuming an eclipse of 7 d from infection to virus RNA detection. Protection was associated with tenofovir levels in vaginal fluid [mean 1.8 × 105 ng/mL (range 1.1 × 104 to 6.6 × 105 ng/mL)] and ex vivo antiviral activity of cervicovaginal lavage samples. These observations support further advancement of TDF IVRs as well as the concept that extended duration drug delivery devices delivering topical antiretrovirals could be effective tools in preventing the sexual transmission of HIV in humans.
- Open Access
- 30 March 2012
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (7) , 1730-1738
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection
A safe and effective topical prevention strategy will likely require sustained delivery of potent antiviral drugs and a delivery system that simultaneously maximizes drug distribution and overcomes the behavioural challenges related to adherence. Activity against HIV and herpes simplex virus (HSV) would be advantageous, given the epidemiological link between the two pathogens. We hypothesize that tenofovir disoproxil fumarate (tenofovir DF), a prodrug of tenofovir, may be more potent than tenofovir and ideal for sustained intravaginal ring (IVR) delivery. The anti-HIV and anti-HSV activity of tenofovir and tenofovir DF were assessed in cell and explant models. Cumulative tenofovir DF release and stability from polyether urethane (PEU), ethylene-co-vinyl acetate (EVA) and silicone IVRs were compared, and the activity and safety of drug released were evaluated in cervical explants and in a polarized dual-chamber model. Tenofovir DF inhibited HIV and HSV at ∼100-fold lower concentrations than tenofovir and retained activity in the presence of semen. PEU rings delivered >1 mg/day of tenofovir DF for 30 days. Pre-treatment of cervical explants with 10 μg/mL tenofovir DF or eluants from PEU minirings resulted in >90% inhibition of HIV and reduced HSV-2 yields by 2.5 log. Tenofovir DF and eluants did not prevent cell growth or polarization, or have any deleterious effects on an epithelial barrier. The findings support the development of a PEU tenofovir DF ring, which may provide potent and sustained protection against HIV and HSV.
- 30 March 2012
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (7) , 1730-1738
Open AccessIntravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection
A safe and effective topical prevention strategy will likely require sustained delivery of potent antiviral drugs and a delivery system that simultaneously maximizes drug distribution and overcomes the behavioural challenges related to adherence. Activity against HIV and herpes simplex virus (HSV) would be advantageous, given the epidemiological link between the two pathogens. We hypothesize that tenofovir disoproxil fumarate (tenofovir DF), a prodrug of tenofovir, may be more potent than tenofovir and ideal for sustained intravaginal ring (IVR) delivery. The anti-HIV and anti-HSV activity of tenofovir and tenofovir DF were assessed in cell and explant models. Cumulative tenofovir DF release and stability from polyether urethane (PEU), ethylene-co-vinyl acetate (EVA) and silicone IVRs were compared, and the activity and safety of drug released were evaluated in cervical explants and in a polarized dual-chamber model. Tenofovir DF inhibited HIV and HSV at ∼100-fold lower concentrations than tenofovir and retained activity in the presence of semen. PEU rings delivered >1 mg/day of tenofovir DF for 30 days. Pre-treatment of cervical explants with 10 μg/mL tenofovir DF or eluants from PEU minirings resulted in >90% inhibition of HIV and reduced HSV-2 yields by 2.5 log. Tenofovir DF and eluants did not prevent cell growth or polarization, or have any deleterious effects on an epithelial barrier. The findings support the development of a PEU tenofovir DF ring, which may provide potent and sustained protection against HIV and HSV.